The research team stated, GLP-1 class drugs are transforming the way we treat obesity, adding, This study suggests that, as the impact of these drugs expands, they may potentially be applied to cancer prevention as well. However, this study does not prove that GLP-1 class obesity drugs directly prevent cancer
It is important to be clear about where the evidence comes from: GHK-Cu is used overwhelmingly topically in cosmetics , where most of its human data small studies of creams and serums for skin firmness, fine lines and wound repair actually lies [6]
Some patients also explore microdosing strategies where they take lower doses more frequently or split their dose across two weekly injections to reduce peak-related side effects
The difference in weight loss is significant
Participation, however, is voluntary
As of February 2026, only Wegovy and Rybelsus are available in pill form